YM BioSciences Announces Pivotal Preclinical Efficacy Data for the JAK1/2 inhibitor CYT387
News Apr 21, 2010
YM BioSciences Inc. has announced the pre-publication of pivotal preclinical data for CYT387, the company’s highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.
The scientific paper, published as a First Edition in the premier hematology journal Blood, describes an extensive body of work demonstrating the potent activity of the compound in in-vitro cell assays and in an in vivo model of the myeloproliferative neoplasms (MPNs).
The paper describes work conducted in the laboratory of Dr Michael Deininger at Oregon Health Sciences University Knight Cancer Institute, Portland, Oregon, which demonstrates that orally-administered CYT387 normalizes the hallmark MPN features of elevated blood cell counts and enlarged spleen size in an in vivo model of the disease. Importantly, blood cell production is shown to return to the bone marrow with drug treatment.
CYT387 also significantly reduces circulating levels of inflammatory cytokines such as IL-6 and TNF-a, which are common in patients with MPNs, as well as in auto-immune diseases such as rheumatoid arthritis. The data are consistent with data reported for INCB18424 (Incyte/Novartis), the other dual JAK1/2 inhibitor in clinical development.
An internal study at YM BioSciences demonstrates that CYT387 possesses similar potency against JAK1/2 enzymes as INCB18424. Moreover, in the same study CYT387 was demonstrated to have improved selectivity over JAK3 and TYK2 than INCB18424, which may result in a superior therapeutic window for CYT387. Results from this comparative study will be submitted for presentation at forthcoming meetings during 2010.
“This extensive study by Dr Deininger and his team clearly demonstrates that our JAK1/2 inhibitor CYT387, has an exceptional profile for the treatment of MPNs,” said David Allan, Chairman and CEO of YM BioSciences. “Our expectation for the clinical success of this compound is reflected in the recent decision by the principal investigator and data safety monitoring board to accelerate the current Phase I/II clinical trial in myelofibrosis through an earlier-than-planned initiation of the Phase II component of the study.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE